Drug Approval | December 03, 2021
Biocon Pharma receives ANDA approval for Mycophenolic acid
This further adds to Biocon’s portfolio of vertically integrated complex drug products
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Biocon Biologics and Viatris co-developed the products
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
